OSAKA, Giappone e CAMBRIDGE, Massachusetts--(BUSINESS WIRE)--Takeda Pharmaceutical CompanyLimited (TSE.4502/NYSE.TAK) (“Takeda”) oggi ha annunciato che lo studio clinico PANTHER (Pevonedistat-3001) di fase 3 non ha conseguito risultati statisticamente significativi ...
TAK) (“Takeda”) a annoncé aujourd’hui que l’étude PANTHER (Pevonedistat-3001) de Phase 3 n'a pas atteint la signification statistique prédéfinie pour le critère principal d’évaluation de survie sans événement (SSÉ) ... L’étude PANTHER de Phase 3 (Pevonedistat-3001) n'a pas atteint la ...
IOVA) has selected Avid to provide process development, pilot-batch manufacturing and CGMP manufacturing services to support development of IOV-3001, a novel antibody cytokine engrafted protein. Cell line development activities for IOV-3001 are currently being conducted by Aragen Bioscience under a subcontracting agreement with Avid.